RxDoctor Payments Data

Jada Bakker

Family · Sioux Falls, SDNPI 1689159667

Payments from drug & device makers

$1,052in general payments, 2019–2025

Across 46 payments — averaging $22.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$213
  • Amgen$110
  • Sanofi-aventis U.S. LLC$94
  • Medtronic$91
  • Amphastar Pharmaceuticals, Inc.$79
  • Boehringer Ingelheim$75
  • plus $391 from 11 others

What the payments were for

  • Food & beverage$1,052100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,052 in reported general payments places this provider in the 75th percentile of 588 family providers in South Dakota.

See all family providers in South Dakota

Medicare billing

Part B allowed, 2024
$32,253
Medicare patients
212
Services billed
581

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide84$90,775
OzempicSemaglutide50$55,429
Fiasp FlextouchInsulin Aspart (Niacinamide)44$39,540
JardianceEmpagliflozin54$33,677
Tresiba Flextouch U-100Insulin Degludec57$31,335
Tresiba Flextouch U-200Insulin Degludec20$27,720
TrulicityDulaglutide15$23,858
Novolog FlexpenInsulin Aspart73$21,067
Victoza 3-PakLiraglutide16$13,235
Humulin R U-500 KwikpenInsulin Regular, Human15$12,711
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog32$10,495
Repatha SureclickEvolocumab16$9,998
VascepaIcosapent Ethyl34$8,834
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$8,763
Humalog Kwikpen U-100Insulin Lispro33$6,550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Baqsimi$34$120,712110 claims
Novo NordiskOzempic$213$55,42950 claims
Boehringer IngelheimJardiance$75$33,67754 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 588 family providers in South Dakota.

Other family in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →